Loading clinical trials...
Loading clinical trials...
2D and 4D Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization
Conditions
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound)
Logiq E9 Scanner (Contrast-enhanced ultrasound)
Locations
3
United States
University of California, San Diego
La Jolla, California, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
April 1, 2016
Primary Completion Date
December 1, 2021
Completion Date
February 1, 2023
Last Updated
May 6, 2025
NCT07175441
NCT05969860
NCT06427941
NCT05842174
NCT07164313
NCT07118202
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions